The mammalian cell expression system, the preferred expression platform for producing mammalian proteins with the most native structure and activity, is commonly used to produce antibodies and therapeutic proteins. CD Formulation is a trusted protein production contract organization committed to providing high-quality mammalian cell expression therapeutic protein production services. Our team has decades of experience and expertise in transient and stable expression based on HEK293 or CHO cell lines, providing customized protein production solutions based on customer needs.
Mammalian cells (CHO cells or HEK293 cells) expression systems are one of the conventional methods for protein production. The advantage is that these cells have highly complex post-transcriptional modification mechanisms, which can effectively produce recombinant proteins with biological activity and correct folding, and are suitable for the production of antibodies, vaccines, and other therapeutic proteins. The expression system of recombinant proteins using mammalian cells can introduce appropriate protein folding, post-translational modifications, and product assembly, essential for complete biological activity. In addition, mammalian cell expression systems also have good biocompatibility and relatively complete genome modification technology, which makes them play an important role in biopharmaceuticals, basic research, and clinical applications.
Fig. 1 Schematic workflow of transient expression process in mammalian cells. (Fu Y, et al., 2024)
As a leading protein production contract organization, CD Formulation is focused on providing high-quality therapeutic protein production services to customers around the world. Our professional team has extensive experience in providing customized solutions for a wide range of biopharmaceutical products.
With our in-house proprietary mammalian cell expression platform, our scientists are able to efficiently produce a variety of therapeutic proteins, including monoclonal antibodies, recombinant proteins, and fusion proteins.
Codon optimization of target sequence according to the codon preference of CHO or HEK293.
Choose the appropriate vector type according to the experimental purpose and clone the cDNA into the expression vector.
We have developed proprietary mammalian cell expression platforms based on HEK293 and CHO cell lines, allowing for high-throughput delivery and high-quality recombinant protein expression.
HEK293 Cell | CHO Cell |
|
|
Expression Platform | Properties | |||||||||
Growth Speed | Expression Level | Production Time | Contamination Risk | Posttranslational Modification | ||||||
Protein Folding | Phosphorylation | Acetylation | N-linked glycosulation | O-linked glycosulation | Acylation | |||||
Yeast | Rapid | Low-High | Medium | Low | Sometimes | Yes | Yes | High Mannitol | Yes | Yes |
Baculovirus-Insect Cell | Slow | Low-High | High | High (e.g., virus) | Suitable | Yes | Yes | Simple | Yes | Yes |
E. coli | Rapid | High | Low | Medium (e.g., endotoxin) | Need | No | No | No | No | No |
Mammalian Cell | Slow | Low-Medium | High | Very high (e.g., virus, DNA) | Suitable | Yes | Yes | Complex | Yes | Yes |
Published Data
Technology: Mammalian Cell (HEK293) Expression System
Journal: Sci Rep.
IF: 3.8
Published: 2020
Results:
The authors developed an experimental approach to systematically assess the expression limit of a target protein in the human embryonic kidney cell line HEK293 by measuring the target protein levels in cells that survived the efficient, multicopy introduction of plasmid DNA. As a proof-of-concept, the expression limit of green fluorescent protein (GFP) and its derivatives as model proteins was estimated. The expression limit of a non-fluorescent target protein was estimated indirectly by measuring the GFP fluorescence of the target protein linked to the self-cleaving sequence P2A.
Fig. 2 Experimental conditions to estimate GFP expression limit in HEK293 cells. (Mori Y, et al., 2020)
Thanks to our in-house advanced mammalian cell expression platform, CD Formulation is committed to providing efficient and economical production of therapeutic proteins. Please don't hesitate to contact us if you are interested in our services. We look forward to cooperating with you.
References